Jove
Visualize
Contact Us

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrin Gel as a Versatile Biomaterial Platform in the Biomedical Landscape: Chemical, Physical, and Biological Insights.

Gels (Basel, Switzerland)·2026
Same author

New Candidate Reference Measurement Procedures for MET CNV Detection and Quantification Using Digital PCR.

Biological procedures online·2026
Same author

Standardized Protocol for Resazurin-Based Viability Assays on A549 Cell Line for Improving Cytotoxicity Data Reliability.

Cells·2024
Same author

Standard Operating Procedure to Optimize Resazurin-Based Viability Assays.

Biosensors·2024
Same author

Risk factors for periprosthetic femoral fractures around total hip arthroplasty: a systematic review and meta-analysis.

ANZ journal of surgery·2019
Same author

State targeted response to the opioid Crisis grants (opioid STR) program: Preliminary findings from two case studies and the national cross-site evaluation.

Journal of substance abuse treatment·2019
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 16, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

The Year's New Drugs & Biologics - 2009.

Ann I Graul1, Lisa Sorbera, Patricia Pina

  • 1Editorial Department, Thomson Reuters, Barcelona, Spain. ann.graul@thomsonreuters.com

Drug News & Perspectives
|February 16, 2010
PubMed
Summary
This summary is machine-generated.

In 2009, 51 new medicines and vaccines were launched. Over 30% were line extensions, with a focus on first-in-class drugs and drug repositioning strategies.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: Jun 16, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

  • Pharmaceuticals and Therapeutics
  • Drug Discovery and Development

Background:

  • Annual review of novel pharmaceutical products.
  • Tracking new drug and biologic approvals is crucial for understanding therapeutic advancements.

Purpose of the Study:

  • To present new drugs and biologics first approved or marketed in 2009.
  • To analyze first-in-class drugs, their mechanisms, and development timelines.
  • To explore drug repositioning as a strategy for extending medication lifespans.

Main Methods:

  • Compilation and analysis of newly launched drugs and biologics from 2009.
  • In-depth review of first-in-class drugs, including their mechanisms of action.
  • Examination of drug discovery and development periods.
  • Assessment of drug repositioning initiatives.

Main Results:

  • 51 new medicines and vaccines reached their first markets in 2009.
  • Line extensions constituted over 30% of new product launches.
  • First-in-class drugs with novel mechanisms were highlighted.
  • Drug repositioning was analyzed as a life-extending strategy.

Conclusions:

  • The year 2009 saw significant new drug and biologic approvals, including innovative first-in-class therapies.
  • Line extensions and drug repositioning play a vital role in the pharmaceutical market.
  • Future market trends and potential new drug launches were briefly considered.